BioSpace News Archive

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp , Chairman and Chief Executive Officer, will participate on the COVID-19 panel at Maxim Group’s Infectious Disease Vi

Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, announced it will release first quarter 2020 financial results after the market closes on Wednesday, May 6th, 2020.

Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced it has enrolled the first patient into its AEROSURF® phase 2b bridging study in premature inf

Enzo Biochem, Inc. (NYSE: ENZ), a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent No. 10,624,863 entitled Sphingosine Kinase Type 1 Inhibitors and Uses Thereof. The patent is directed to methods for inhibiting the enzyme Sphingosine kinase 1 in patients using the company’s proprietary compound SK1-I and related Sphingosine kinase 1 inhibitors. In February, Enzo reported the publication of work

Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, May 7, 2020, to provide a corporate update and discuss details of the Company’s financial results for the quarter ended March 31, 2020. To access

Global Blood Therapeutics, Inc. announced that it will report first quarter 2020 financial results on Wednesday, May 6, 2020, after U.S. financial markets close..

Innovative Cellular Therapeutics, a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor T cell therapies for solid and liquid tumors, announced details of two abstracts on its novel CoupledCAR® solid tumor CAR-T technology for treating colorectal and thyroid cancers.

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the company will present preclinical data from its oncology pipeline of Red Cell Therapeutics™ (RCTs) at the American Society of Gene and Cell Therapy (ASGCT) 23 rd Annual Meeting. The meeting is being held virtually from May 12 – 15, 2

On track to initiate the OPTION 2 trial by the end of Q2 2020 OPTION 2 trial to compare efficacy of standard of care to 2.2 and 4.4 gram doses of MS1819 in enteric capsules Trial completion and top-line data expected in Q1 2021 NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the Company rece

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its first quarter 2020 on Wednesday, May 6, 2020. Management will host a conference call to review the results at 8:30 AM ET on the same day. The conference call may be accessed by dialing (877) 312-7507 from the U.S. and Canada or (631) 813-4828 from international locat